HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

Executive Summary

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.

You may also be interested in...



Herbalife Raises 2021 Outlook As Largest Markets See Double-Digit Growth In Q1

Herbalife Nutrition's North American, Asia Pacific and EMEA regions recorded sales growth in excess of 20% each in the first quarter, as sales of energy, sports and fitness products soared 34%. The Los Angeles-based MLM company raised its full-year guidance accordingly, projecting net sales gains of 9% to 15%.

Herbalife Pays $123M To Resolve Criminal, Civil Charges From US Investigation Of China Business

Direct seller pays fines in settlements with SEC and DoJ on bribery and other charges but two former executives for its operations in China still face criminal charges alleging violations of the Foreign Corrupt Practices Act. They have not been arrested and have remained at large since being charged in November 2019.

Coronavirus Drives TCM Sales In China, Clouds Global Consumer Health Outlook

Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS149723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel